Healios KK (JP:4593)
:4593
Want to see JP:4593 full AI Analyst Report?
4593 Stock Chart & Stats
¥370.00
¥3.00(1.60%)
At close: 4:00 PM EST
¥370.00
¥3.00(1.60%)
Day’s Range― - ―
52-Week Range¥255.00 - ¥747.00
Previous CloseN/A
Volume811.70K
Average Volume (3M)1.65M
Market Cap
¥42.80B
Enterprise Value¥27.79B
Total Cash (Recent Filing)¥10.87B
Total Debt (Recent Filing)¥2.59B
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 18, 2026EPS Estimate
-2.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.18
Shares Outstanding135,002,200
10 Day Avg. Volume1,843,110
30 Day Avg. Volume1,654,023
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥965.00Price Target Upside160.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-40.95
Revenue Forecast (FY)¥531.42M
Bulls Say, Bears Say
Bulls Say
Regenerative Medicine SpecializationHealios’ concentrated focus on cell therapy and regenerative medicine in ophthalmology and acute neurology creates durable strategic clarity. These high-barrier, indication-specific programs support long development horizons and potential high-value outcomes that underpin long-term partnership and commercialization opportunities.
Defined Monetization Pathways (partnering/licensing)The company’s stated model—progressing assets then monetizing through partnerships, licensing, or direct commercialization—provides enduring strategic flexibility. This reduces reliance on near-term product sales and allows risk-sharing and non-dilutive funding options to sustain R&D over multiple clinical stages.
Improved Leverage And Larger Equity CushionLeverage materially improved versus prior years and equity has risen, creating a clearer capital cushion. This moderates short-to-medium-term financing risk and gives management more runway to advance clinical programs or negotiate partnerships without immediate pressure to raise dilutive capital.
Bears Say
Large And Persistent Cash BurnSustained negative operating and free cash flow at multi-billion-yen annualized rates creates a durable financing imperative. Over the next several months management will need new capital or partner funding; repeated funding rounds risk dilution and can constrain timing and scope of clinical development decisions.
Deep Unprofitability With Sharply Shrinking RevenueThe combination of very large net losses and materially declining revenue signals weak near-term commercial traction. This structural mismatch between costs and sales makes the pathway to self-sustaining operations uncertain and increases dependence on external financing or partnerships to continue development.
Negative Returns Eroding Shareholder ValuePersistently negative ROE shows the company is destroying equity despite a stronger balance sheet. Over time this reduces investor confidence and narrows strategic options, forcing management toward dilutive financing, asset sales, or accelerated partner deals that may compromise long-term upside for shareholders.
Healios KK News
4593 FAQ
What was Healios KK’s price range in the past 12 months?
Healios KK lowest stock price was ¥255.00 and its highest was ¥747.00 in the past 12 months.
What is Healios KK’s market cap?
Healios KK’s market cap is ¥42.80B.
When is Healios KK’s upcoming earnings report date?
Healios KK’s upcoming earnings report date is Aug 18, 2026 which is in 75 days.
How were Healios KK’s earnings last quarter?
Healios KK released its earnings results on May 14, 2026. The company reported -¥27.65 earnings per share for the quarter, missing the consensus estimate of -¥11.14 by -¥16.51.
Is Healios KK overvalued?
According to Wall Street analysts Healios KK’s price is currently Undervalued.
Does Healios KK pay dividends?
Healios KK does not currently pay dividends.
What is Healios KK’s EPS estimate?
Healios KK’s EPS estimate is -2.43.
How many shares outstanding does Healios KK have?
Healios KK has 135,002,200 shares outstanding.
What happened to Healios KK’s price movement after its last earnings report?
Healios KK reported an EPS of -¥27.65 in its last earnings report, missing expectations of -¥11.14. Following the earnings report the stock price went down -1.163%.
Which hedge fund is a major shareholder of Healios KK?
Currently, no hedge funds are holding shares in JP:4593
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Healios KK
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
4593 Stock 12 Month Forecast
Average Price Target
¥965.00
▲(160.81% Upside)
Technical Analysis
SanBio Co
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---